A venture capital firm made about $470 million on a buzzy biotech's $8 billion acquisition, and has its eye on these promising areas next

Österreich Nachrichten Nachrichten

Aisling Capital managing partner Steve Elms told Business Insider about the other biotechs and scientific areas the firm is intrigued by.